Company Encyclopedia
View More
name
New Journey
002219.SZ
New Journey Health Technology Group Co.,LTD, together with its subsidiaries, provides medical services and pharmaceuticals products in China and internationally. The company operates regional medical centers to treat aging diseases, such as tumors, cardiovascular, cerebrovascular, and orthopedics. It is also involved in the research, development, production, and sale of medicines comprising Duyiwei capsules, Ginsengqi Schisandra tablets, Maiping tablets, Prosta Antong tablets, Gongzhongning capsules, Wuhu San, Wei Funing capsules, and other proprietary Chinese medicine products. In addition, it engages in Chinese herbal medicine planting; investment management; retail business; wholesale trading activities; and provision of resident services.
173.94 B
002219.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care FacilitiesIndustry
Industry Ranking8/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.91%D
    • Profit Margin0.63%C
    • Gross Margin24.02%C
  • Growth ScoreE
    • Revenue YoY-28.55%E
    • Net Profit YoY-62.54%D
    • Total Assets YoY6.01%B
    • Net Assets YoY-14.07%E
  • Cash ScoreC
    • Cash Flow Margin15881.84%A
    • OCF YoY-28.55%E
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreD
    • Gearing Ratio69.13%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    New Journey Health Technology Group Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2025

    New Journey Health Technology Group Co.,LTD reported a net loss of CNY 38.47 million for the nine months ended September 30, 2025, down from a net income of CNY 56.72 million the previous year. Sales decreased to CNY 2,256.1 million from CNY 2,945.3 million. Basic and diluted loss per share from continuing operations were both CNY 0.0114, compared to earnings of CNY 0.0166 per share a year ago.

    marketscreener·
    SZ
    002219
    +1.75%
    marketscreener·
    SZ
    002219
    +1.75%

    22:45 ET The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development

    The 2025 BPD Singapore Summit, co-hosted by WuXi XDC, successfully concluded from September 24-26, 2025. The event gathered leading biopharmaceutical companies and research institutions globally to enhance cooperation and promote advanced process technologies in drug manufacturing. Keynote speeches highlighted technological advancements and their impact on cost optimization. A forum on "XDC Innovation and Development" featured discussions on bioconjugate drugs and their evolution, emphasizing the importance of innovation and collaboration in the biopharmaceutical industry. WuXi XDC showcased its capabilities in supporting the internationalization of innovative drugs, focusing on quality and customer satisfaction.

    prnewswire·
    SZ
    002219
    +1.75%
    prnewswire·
    SZ
    002219
    +1.75%

    New Journey provides guarantees for a total credit of 80 million yuan for two subsidiaries

    New Journey agreed to provide a total guarantee of 80 million yuan for its wholly-owned subsidiaries Wafangdian Third Hospital and Lankao First Hospital, with a guarantee period of three years. This guarantee is part of the 1.814 billion yuan joint liability guarantee provided by the company for the comprehensive credit of its subsidiaries over the next 12 months. As of June 30, the actual guarantee balance was 702 million yuan, accounting for 35.39% of the audited net assets. The board of directors believes that the guarantee risk is controllable and will not harm the interests of the company and its shareholders

    Zhitong·
    SZ
    002219
    +1.75%
    Zhitong·
    SZ
    002219
    +1.75%

    New Journey Health Says Local Authorities Has Lifted Detention Measures On Chairman Lin Yanglin

    New Journey Health Technology Group Co Ltd :SAYS LOCAL AUTHORITIES HAS LIFTED DETENTION MEASURES ON CHAIRMAN LIN YANGLINSAYS LIN IS ABLE TO PERFORM HIS CHAIRMAN DUTIES; CO. IS IN NORMAL PRODUCTION AND OPERATIONS

    Reuters·
    SZ
    002219
    +1.75%
    Reuters·
    SZ
    002219
    +1.75%

    New Journey Chairman Lin Yanglin has been released from the detention measures

    New Journey Chairman Lin Yanglin has been released from the detention measures and has resumed normal duties. Previously, Lin Yanglin was detained and investigated by the Xiaodian District Supervisory Committee of Taiyuan City. On September 21, 2025, the company received a notice of release from detention, and Lin Yanglin is now able to perform his duties normally, with the company's production and operation situation also returning to normal. Xu Minggui will no longer act on behalf of the Chairman's duties

    Zhitong·
    SZ
    002219
    +1.75%
    Zhitong·
    SZ
    002219
    +1.75%
    © 2025 Longbridge｜Disclaimer